Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation
AP30663 achieved proof of mechanism with first-in-class SK channel inhibition compound in atrial fibrillation – primary endpoint met:...
top of page
Sep 26, 20235 min read
Acesion Pharma Closes Oversubscribed €45M Series B Financing Round
Financing co-led by new investors Canaan and Alpha Wave, and with participation by the Global BioAccess Fund and existing investor Novo...
1,399 views
May 15, 20234 min read
Acesion Pharma Announces Positive Pre-Clinical Data for AP31969
Copenhagen, Denmark – Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial...
1,279 views
LATEST NEWS
bottom of page